ISRRT 150614

Comprehensive Cancer Center Tampere (TAMCAN)

ISRRT 15.6.2014 Anne Kairenius

Pirkanmaa Hospital District – Anne Kahiluoto2 02.05.23

Tampere University Hospital


Introduction The working group of the Ministry of Social Affairs and Health

proposes that the Finnish comprehensive cancer center comprise a national coordinating centre and five regional centres which could function in close association with existing university hospitals and the catchment areas for providing specialist care.

Financing: Initially, operations would need to be funded mainly from the state budget and would require funding from a main title of expenditure of the Ministry of Social Affairs and Health for a minimum period of three years.

The better the center is able to integrate nationally diagnostics and care with high quality research and teaching, the more significant Comprehensive Cancer Center Finland’s (FICAN) added value will be. FICAN will ensure equitable access to high quality care for cancer patients in Finland beyond 2020.


Introduction Comprehensive Cancer Center Finland (FICAN) = national

coordinating center (Helsinki) and five regional centres (Helsinki, Kuopio, Oulu, Tampere, Turku)

The cancer center will ensure a high quality treatment to Finnish cancer patients with comparable and cost-effective care transition. The number of cancer patients is increasing and the cancer treatment becomes more and more individual

Cancer diseases are becoming one of the most important chronic diseases worldwide


Introduction In Finland, one in four deaths is caused by cancer The rate of cancer is increasing every year, with the population

living longer and the aging of the baby-boom generation willtriple cancer costs from 2004 to 2020 (EUR 1.5 billion / year)

The aim is individually tailored therapies (personalized medicine)efficiently and effectively

Cost-effective cancer treatments can be developed only by integrating treatment to clinical and translational research

To achieve aims integrated care lines are needed The response to challenges has been Comprehensive Cancer

Centers, which integrate cancer treatment and research past 50 years in the US (42 centers, Europe 7)


Introduction Our multi-disciplinary treatment team consists of different types of

expertise, which addresses the patient's disease: surgery, chemotherapy, radiation therapy, pathology, genetics, imaging, palliative care, psychosocial support and rehabilitation

According to international statistics the cancer treatment results in our country are in the level of high international standard, but rapidly increasing of research and its exploitation set new requirements for the implementation of cancer treatment

By using molecular biology and cell biology methods more and more growth path errors will be found in cancers. Errors can be affected by the regulation of new drugs

Scientists may not have found cures for all forms of cancer, but researchers have discovered numerous ways to treat and manage many of the more than 200 variations of this disease


What is TAMCAN? The task is to promote cancer treatment, research and training Know-how especially in the wide-ranging prostate and breast cancer study Supports also other types of cancer research and high-quality care Phase I-II center (early-stage clinical trials are at a low level for the future) Produces research services, and develops new innovations in translational

research (forms a bridge between basic research and patient care) in cancer treatment and prevention

The aim is that every tenth patient visit should be associated to research TAMCAN organizes high-quality research training for catchment areas as

well as nationally and internationally, in conjunction with the University and the University of Applied Sciences

New drugs given to patients are research based


Operations and customers The main customer groups are: Pirkanmaa Hospital District's

municipalities and patients, the catchment areas of the central hospitals (Pirkanmaa, Lahti, Hämeenlinna, Vaasa), pharmaceutical industry, surgery, radiotherapy and diagnostic equipment manufacturers, domestic and international research community and patient organizations

Clinical cancer trials save approximately 1.5 million euros annually


Objectives TAMCAN combines:

• basic• translational• clinical• public health• scientific research and service system in cancer prevention• screening• diagnostics• treatment and rehabilitation with development.

Finland's leading cancer research center in the overall patient treatment and on the top of international level, and in other selected research areas at the good international level by the year 2020.

National Center of the Cancer education


Phase I-II trial center To investigate the first time cancerdrug effects in humans to

molecule drug absorption, distribution, metabolism, or excretion of the human body

The trials is to find treatments that are more effective in controlling cancer with fewer side effects

Small number of patients in trials The intention is to carry out research projects, which are in Finland

scientifically necessary Development of drugs that affect specific targets in the cancer cell is

important. Clinical trials validate the efficacy of these drugs To develop more effective therapy to different type of cancers

personalized medicine


Phase I-II trial center Patients are mainly from Finland, but also from Estonia and Russia New and modern specialization to medical oncology and radiation

therapy, clinical hematology and pharmacology, as well as specialized gynecological oncology

Studies can allow participants to benefit from the newest treatments for several years before they become available at a pharmacy

First in Finland Situated in oncology ward with four beds


Staff Employed by a hospital or university

Phase I-II- trialcenter hospital staff: 2 doctors, four research nurses, research coordinator, research assistant

Our medical staff have close ties to prominent hospitals and current cancer research, and we bring those breakthrough advances to our regional centers to progress the level of care


Success Factors Services that support Clinical studies can be implemented uniformly

with the other national centers and international centers


What are the biggest barriers to moving cancer research forward faster?

By far our greatest barrier is the lack of money and resources going into research. Many research ideas or grants that should be funded do not get funded due to lack of money.

A second major issue is the lack of adults participating in cancer clinical treatment trials.


Organization The organization of TAMCAN consists of board of TAMCAN,

scientific expert group and board of directors all working in Tampere university hospital or in Tampere university.


Schedule

Phase I-II Research Center 1/2015 Extension 1/2016


Contact

[email protected]

Documents

ISRRT 150614